These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 27390130

  • 1. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, Richards HB, Martin R, Porter B.
    Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
    [Abstract] [Full Text] [Related]

  • 2. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
    van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, Thompson C, Sieper J, ATLAS Study Group.
    Arthritis Res Ther; 2009 Dec; 11(4):R124. PubMed ID: 19686597
    [Abstract] [Full Text] [Related]

  • 3. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
    Navarro-Compán V, Wei JC, Van den Bosch F, Magrey M, Wang L, Fleishaker D, Cappelleri JC, Wang C, Wu J, Dina O, Fallon L, Strand V.
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35654457
    [Abstract] [Full Text] [Related]

  • 4. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD, Hwang MC, Danve A, Kafka S, Peterson S, Lo KH, Kim L, Hsia EC, Chan EKH, Deodhar A.
    Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.
    Arthritis Res Ther; 2017 Dec 22; 19(1):285. PubMed ID: 29273067
    [Abstract] [Full Text] [Related]

  • 6. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R.
    J Rheumatol; 2014 Jun 22; 41(6):1067-76. PubMed ID: 24786931
    [Abstract] [Full Text] [Related]

  • 7. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
    Davis JC, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP.
    Arthritis Rheum; 2007 Aug 15; 57(6):1050-7. PubMed ID: 17665483
    [Abstract] [Full Text] [Related]

  • 8. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.
    Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D.
    Rheumatology (Oxford); 2010 Apr 15; 49(4):812-9. PubMed ID: 20100797
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B.
    Int J Rheum Dis; 2017 May 15; 20(5):589-596. PubMed ID: 28544533
    [Abstract] [Full Text] [Related]

  • 10. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
    Navarro-Compán V, Baraliakos X, Magrey M, Östör A, Saffore CD, Mittal M, Song IH, Ganz F, Stigler J, Deodhar A.
    Rheumatol Ther; 2023 Jun 15; 10(3):679-691. PubMed ID: 36820984
    [Abstract] [Full Text] [Related]

  • 11. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C, GO-RAISE investigators.
    J Rheumatol; 2014 Jun 15; 41(6):1095-103. PubMed ID: 24737912
    [Abstract] [Full Text] [Related]

  • 12. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
    Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B, Measure 2 Study Group.
    Arthritis Care Res (Hoboken); 2017 Jul 15; 69(7):1020-1029. PubMed ID: 28235249
    [Abstract] [Full Text] [Related]

  • 13. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
    Reveille JD, Deodhar A, Ince A, Chan EKH, Peterson S, Li N, Hsia EC, Kim L, Lo KH, Xu S, Harrison DD, Han C.
    Value Health; 2020 Oct 15; 23(10):1281-1285. PubMed ID: 33032770
    [Abstract] [Full Text] [Related]

  • 14. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
    Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D.
    J Rheumatol; 2010 Feb 15; 37(2):385-92. PubMed ID: 19955052
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb 15; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 16. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
    Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W.
    J Rheumatol; 2008 Apr 15; 35(4):662-7. PubMed ID: 18278836
    [Abstract] [Full Text] [Related]

  • 17. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD, Deodhar A, Caldron PH, Dudek A, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.
    J Rheumatol; 2019 Oct 15; 46(10):1277-1283. PubMed ID: 30824635
    [Abstract] [Full Text] [Related]

  • 18. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, MEASURE 1 study group.
    Ann Rheum Dis; 2017 Jun 15; 76(6):1070-1077. PubMed ID: 27965257
    [Abstract] [Full Text] [Related]

  • 19. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
    Kvien TK, Conaghan PG, Gossec L, Strand V, Østergaard M, Poddubnyy D, Williams N, Porter B, Shete A, Gilloteau I, Deodhar A.
    Arthritis Care Res (Hoboken); 2022 May 15; 74(5):759-767. PubMed ID: 33227175
    [Abstract] [Full Text] [Related]

  • 20. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis.
    Sağ S, Nas K, Sağ MS, Tekeoğlu İ, Kamanlı A.
    J Back Musculoskelet Rehabil; 2018 May 15; 31(3):499-505. PubMed ID: 29504521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.